22.418 articles found

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.

Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ.

Mov Disord · 2005-02-01

DOI: 10.1002/mds.20276PMID: 15390035

Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.

Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield SB.

Neurology · 2005-02-01

DOI: 10.1212/01.wnl.0000152046.11390.45PMID: 15728303

Levodopa-responsive posttraumatic parkinsonism is not associated with changes of echogenicity of the substantia nigra.

Kivi A, Trottenberg T, Kupsch A, Plotkin M, Felix R, Niehaus L.

Mov Disord · 2005-02-01

DOI: 10.1002/mds.20323PMID: 15551348

Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats.

Arica B, Kaş HS, Moghdam A, Akalan N, Hincal AA.

J Control Release · 2005-02-01

DOI: 10.1016/j.jconrel.2004.11.004PMID: 15681090

Stem cell therapy grows on Parkinson's-afflicted monkeys.

Eisenstein M.

Lab Anim (NY) · 2005-02-01

DOI: 10.1038/laban0205-10aPMID: 15685179

Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.

Yamada M, Mizuno Y, Mochizuki H.

Hum Gene Ther · 2005-02-01

DOI: 10.1089/hum.2005.16.262PMID: 15761265

Therapeutic electrical stimulation of the central nervous system.

Benabid AL, Wallace B, Mitrofanis J, Xia C, Piallat B, Fraix V, Batir A, Krack P, Pollak P, Berger F.

C R Biol · 2005-02-01

DOI: 10.1016/j.crvi.2004.10.011PMID: 15771004

Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in Parkinson's disease.

Perlemoine C, Macia F, Tison F, Coman I, Guehl D, Burbaud P, Cuny E, Baillet L, Gin H, Rigalleau V.

Br J Nutr · 2005-02-01

DOI: 10.1079/bjn20041297PMID: 15788112

A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets.

Iravani MM, Syed E, Jackson MJ, Johnston LC, Smith LA, Jenner P.

Eur J Neurosci · 2005-02-01

DOI: 10.1111/j.1460-9568.2005.03915.xPMID: 15787691

COMBINATION OF A NMDA RECEPTOR ANTAGONIST AND A MAO-INHIBITOR OR A GADPH-INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM-RELATED CONDITIONS

WENT Gregory T., MEYERSON Lawrence, FULTZ Timothy J..

· 2005-01-31

Protecting cell therapy for neurological disorders including Parkinson's disease

ABELIOVICH ASA, MARTINAT CECILE.

· 2005-01-31

COMBINATION OF A NMDA RECEPTOR ANTAGONIST AND A MAO-INHIBITOR OR A GADPF-INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM-RELATED CONDITIONS

WENT GREGORY T, MEYERSON LAWRENCE, FULTZ TIMOTHY J.

· 2005-01-31